Leerink Partners analyst Puneet Souda maintained a Buy rating on Danaher on July 22 and set a price target of $235.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Puneet Souda has given his Buy rating due to a combination of factors that highlight Danaher’s strong position in the bioprocessing market and its potential for continued growth. Despite a slight underperformance in biotech growth compared to guidance, the core bioprocessing business showed robust performance with high single-digit growth. This positive trend in orders and backlog-to-bill ratio indicates a healthy demand environment.
Additionally, Danaher’s management has expressed confidence in achieving 5-6% organic growth and an EPS of approximately $8.50 by 2026, which supports a favorable long-term outlook. The company’s leadership in the bioprocess tools market and its diversified operations in life sciences and diagnostics further solidify its status as a high-quality investment. These factors contribute to the reiterated price target of $235, underscoring the analyst’s optimism about Danaher’s future prospects.
In another report released yesterday, Jefferies also reiterated a Buy rating on the stock with a $230.00 price target.
DHR’s price has also changed moderately for the past six months – from $244.180 to $189.910, which is a -22.23% drop .